ImportantUpdates
Concord Biotech secured USFDA approval for Mycophenolate Mofetil oral suspension, an immunosuppressant.
Concord Biotech LimitedCONCORDBIO · Filed with the exchange
This product targets a US market estimated at US$ 30 million (approx ₹249 Cr), boosting the company's offerings and growth strategy.
No comments yet. Be the first.